Company Overview of Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company develops exosome-based diagnostics technology platform that harvests comprehensive and dynamic molecular information contained within exosomes from various fresh or frozen biofluids to deliver personalized healthcare to guide treatment decisions and in real-time along the entire patient care continuum. Its technology combines RNA analysis with DNA and protein analysis to deliver comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated, and monitored. The company al...
Riverside Technology Center
840 Memorial Drive
Cambridge, MA 02139
Founded in 2008
Key Executives for Exosome Diagnostics, Inc.
Chief Executive Officer and President
Chief Science Officer and Founding Scientist
Head of Commercial Diagnostics
Compensation as of Fiscal Year 2016.
Exosome Diagnostics, Inc. Key Developments
Exosome Diagnostics Signs an Agreement with Merck to Help Advance the Development of New Drugs
Feb 10 17
Exosome Diagnostics has signed an agreement with Merck to help advance the development of new drugs in oncology and other therapeutic areas using the former’s proprietary technology platforms that span across nucleic acid and protein.
Exosome Diagnostics, Inc. Obtains ISO 15189 for its Munich Laboratory
Jan 18 17
Exosome Diagnostics, Inc. announced that it has received ISO 15189 certification for its Munich laboratory, thereby paving the way to process clinical samples in Asia, Europe, the Middle East, and Russia, more efficiently. Combined with the company’s CLIA certified Cambridge laboratory, the Munich laboratory and offices will serve as an integral part of the company’s diagnostic strategy to better the lives of patients worldwide. In September 2016, Exosome Diagnostics launched its diagnostic test for prostate cancer, ExoDx Prostate Intelliscore (EPI), to determine whether a patient who presented with a PSA in the gray zone needed to proceed with a biopsy. In the United States each year, approximately one million prostate biopsies are performed with up to 80% of the results indicating no cancer, or a low-grade cancer that could instead be monitored under a watchful waiting or active surveillance program. The EPI test was designed to reduce the number of unnecessary prostate biopsies and the associated overtreatment of low-grade disease. Complications associated with unnecessary prostate tissue biopsies range from discomfort and temporary incontinence or impotence, to hospitalization for serious infections in three to four percent of patients.
Exosome Diagnostics, Inc. Presents at 19th Annual BIO CEO & Investor Conference, Feb-13-2017
Jan 3 17
Exosome Diagnostics, Inc. Presents at 19th Annual BIO CEO & Investor Conference, Feb-13-2017 . Venue: The Waldorf Astoria New York, 301 Park Avenue, New York, NY 10022, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|